Objective: This study aimed to investigate the role of tRNA-derived RNA fragment tRF-Pro-CGG in pancreatic cancer (PC), focusing on its expression levels in PC tissues and cell lines, and its effects on cell proliferation, clonality, migration, invasion, and apoptosis. Additionally, the study explored the potential of tRF-Pro-CGG as a diagnostic biomarker and therapeutic target in PC.
Methods: The expression levels of tRF-Pro-CGG in PC tissues and cell lines were analyzed using next-generation sequencing and quantitative real-time PCR (qRT-PCR). Functional assays, including cell proliferation (CCK-8), colony formation, migration (Transwell), invasion (Matrigel), and apoptosis (flow cytometry), were conducted on PC cell lines (SW1990 and PANC-1) transfected with tRF-Pro-CGG mimic or inhibitor. Dual luciferase reporter assays and Western blotting were used to identify and validate the target gene of tRF-Pro-CGG, CSF1, and its involvement in the PI3K-AKT signaling pathway.
Results: tRF-Pro-CGG was significantly downregulated in PC tissues and cell lines compared to normal tissues and cells. Overexpression of tRF-Pro-CGG in SW1990 cells inhibited cell proliferation, clonality, migration, and invasion, while promoting apoptosis. Conversely, inhibition of tRF-Pro-CGG in PANC-1 cells had the opposite effects. Dual luciferase assays confirmed CSF1 as a direct target of tRF-Pro-CGG, and Western blot analysis showed that tRF-Pro-CGG negatively regulated CSF1 expression. Furthermore, tRF-Pro-CGG was found to modulate the PI3K-AKT signaling pathway, with downstream effects on key molecules such as AKT, P-AKT, and PTEN.
Conclusion: tRF-Pro-CGG acts as a tumor suppressor in pancreatic cancer by inhibiting cell proliferation, migration, invasion, and promoting apoptosis, likely through targeting CSF1 and regulating the PI3K-AKT signaling pathway. These findings suggest that tRF-Pro-CGG could serve as a potential diagnostic biomarker and therapeutic target for pancreatic cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-025-08943-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long term latency of highly mutated cells in normal mouse skin is reversed by exposure to tumor promoters and chronic tissue damage.
Cancer Discov
March 2025
University of California, San Francisco, San Francisco, CA, United States.
Historical studies performed nearly a century ago using mouse skin models identified two key steps in cancer evolution: initiation, a likely mutational event, and promotion, driven by inflammation and cell proliferation. Initiation was proposed to be permanent, with promotion as the critical rate-limiting step for cancer development. Here, we carried out whole genome sequencing to demonstrate that initiated cells with thousands of mutagen-induced mutations can persist for long periods and are not removed by cell competition or by immune intervention, thus mimicking the persistence of cells with cancer driver mutations in normal human tissues.
View Article and Find Full Text PDFIt is known that inhibition of the endoplasmic reticulum transmembrane signaling protein (ERN1) suppresses the glioblastoma cells proliferation. The present study aims to investigate the impact of inhibition of ERN1 endoribonuclease and protein kinase activities on the , , and gene expression in U87MG glioblastoma cells with an intent to reveal the role of ERN1 signaling in the regulation of expression of these genes. The U87MG glioblastoma cells with inhibited ERN1 endoribonuclease (dnrERN1) or both enzymatic activities of ERN1 (endoribonuclease and protein kinase; dnERN1) were used.
View Article and Find Full Text PDFEarly expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes.
J Immunol
January 2025
Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, United States.
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity.
View Article and Find Full Text PDFImpact of obesity on the CCR6-CCL20 axis in epidermal γδ T cells and IL-17A production in murine wound healing and psoriasis.
J Immunol
January 2025
Department of Biological Sciences, California State University San Marcos, San Marcos, CA, United States.
Obesity is associated with comorbidities including type 2 diabetes, chronic nonhealing wounds, and psoriasis. Normally, skin homeostasis and repair is regulated through the production of cytokines and growth factors derived from skin-resident cells including epidermal γδ T cells. However, epidermal γδ T cells exhibit reduced proliferation and defective growth factor and cytokine production during obesity and type 2 diabetes.
View Article and Find Full Text PDFSuppression of NF-κB and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion.
J Immunol
January 2025
Institute of Microbiology and Immunology, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
Decoy receptor 3 (DcR3), a soluble receptor in the tumor necrosis factor receptor superfamily, regulates the functions of monocytes, macrophages, dendritic cells, and T cells. Previous studies have demonstrated that DcR3 suppresses B cell proliferation in vitro and ameliorates autoimmune diseases in animal models; however, whether and how DcR3 regulates antibody production is unclear. Using a DcR3 transgenic mouse model, we found that DcR3 impaired the T cell-dependent antigen-stimulated antibody response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!